Clinical information
Diagnostic Utility:
This is the qualitative detection of nucleic acids from the West Nile Virus (WNV), and its determination is useful in:
- Identification of individuals with active WNV infection.
- Blood component transfusion.
- Transplantation of progenitor cells, solid organs, and tissues.
- Screening of infectious diseases in egg and semen donors.
Method:
Amplification by Transcription-Mediated Amplification (TMA).
Reference Values
Possible results are: Reactive and Non-Reactive.
Diagnostic Algorithm:
Not applicable.
Response Time:
Maximum of 2 working days.
Specimen information
Sample: Plasma and/or serum from living and/or cadaveric individuals.
Tube: 1-5 mL aliquots, plasma tubes with EDTA, ACD, heparin, or sodium acetate; and/or serum tubes without gel separator.
Minimum essential volume: 1 ml
Stability:
- At room temperature: 3 days for samples from living individuals and 1 day for cadaveric samples.
- At 2-8 ºC: 8 days for samples from both living and cadaveric individuals.
- Frozen sample at or below -20ºC: 10 years
Transport instructions: Preferably at room temperature and/or refrigerated if they are whole blood tubes; frozen if they are serum and/or plasma aliquots.
Reasons for rejection: Sample heavily hemolyzed.
Administrative information
BST Code: 0250
Test Description: West Nile Virus, RNA (TMA). Screening
Synonyms: RNA WNV, West Nile Virus, NAT WNV
Section: Transfusional Safety Laboratory
BST Fee: Check the updated fees here.
Profiles:
Not applicable.
References
- Procleix WNV assay on the Procleix Panther System insert.
Quality
BST holds ISO 9001, ISO 14001, and OSHAS 18001 quality certifications, as well as the European Excellence 500+ seal. BST is accredited by CAT, JACIE-FACT, FACT-NETCORD, and EFI, and complies with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) guidelines.